Skip to main content
IMMUNIC, INC. logo

IMMUNIC, INC. — Investor Relations & Filings

Ticker · IMUX ISIN · US4525EP1011 LEI · 549300R5T12FW5MEQB20 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2026-05-19 Board/Management Inform…
Country US United States of America
Listing US IMUX

About IMMUNIC, INC.

https://imux.com/

Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of selective, orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's mission is to create high-quality, oral treatment options that offer comprehensive therapeutic efficacy with favorable safety and tolerability profiles. Its clinical development programs target conditions with significant unmet medical needs, including multiple sclerosis and celiac disease, aiming to provide patients with convenient and effective solutions to manage debilitating symptoms and improve their quality of life.

Recent filings

Filing Released Lang Actions
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Board/Management Information Classification · 95% confidence The document is a corporate press release announcing the appointment of Michael W. Bonney as Chair of the Board of Directors. It focuses on changes in the company’s board leadership and does not provide financial statements, voting results, or regulatory filings. Therefore, it best fits the “Board/Management Information” category.
2026-05-19 English
8-K - IMMUNIC, INC. (0001280776) (Filer)
Regulatory Filings
2026-05-13 English
10-Q - IMMUNIC, INC. (0001280776) (Filer)
Interim / Quarterly Report
2026-05-13 English
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Earnings Release Classification · 94% confidence The document is a press release announcing Immunic, Inc.’s first quarter 2026 financial results, including revenue, expenses, net loss per share, cash position, corporate updates, and management commentary. It is not the full quarterly regulatory filing (which would include complete financial statements and notes), but rather the initial earnings announcement summarizing key highlights. Therefore, it fits the definition of an Earnings Release (ER). Q1 2026
2026-05-13 English
Immunic to Participate in Investor and Medical Conferences in May
Regulatory Filings Classification · 95% confidence The document is a press release announcing Immunic's participation in upcoming investor and medical conferences in May 2026. It details the dates, locations, and topics of presentations and posters but does not contain any financial statements, earnings data, or detailed financial analysis. There is no indication that this is a transcript of a call, a report, or a regulatory filing. The content is primarily informational about upcoming events and presentations, which aligns with an Investor Presentation announcement or update. However, since it is a news announcement about participation in conferences rather than the presentation materials themselves, it fits best under Regulatory Filings (RNS) as a general regulatory announcement or corporate news. The document length is 9351 characters, which is substantial but the content is clearly a news announcement rather than a detailed report or presentation document.
2026-04-30 English
8-K - IMMUNIC, INC. (0001280776) (Filer)
Regulatory Filings
2026-04-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.